AUS
NZ
UK
CA
USA
IND
Highlights
- Clarity Pharmaceuticals (CU6) secures copper-64 supply for prostate cancer trials
- Fast-track designation by the FDA accelerates research progress
- Partnership strengthens local research and patient care initiatives
Clarity Pharmaceuticals (ASX:CU6) has entered into a strategic agreement with the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland for the ongoing supply of copper-64 (Cu-64) isotope. This critical component will be used in the production of the diagnostic agent 64Cu-SAR-bisPSMA, advancing multiple prostate cancer clinical trials.
The agreement supports Clarity’s Phase III Clarify and Amplify registrational trials, the investigator-initiated Co-PSMA trial, and the SECuRE theranostic trial, all conducted in Australia. Additionally, this collaboration will enhance pre-clinical research efforts, including the SAR-bisFAP and SAR-trastuzumab theranostic programs.
Enhancing Cancer Treatment Through Collaboration
Clarity’s executive chair, Dr. Alan Taylor, emphasized the importance of this partnership in strengthening ties with Australia’s scientific and clinical communities. He noted that such collaborations are crucial in accelerating research and development efforts aimed at improving cancer treatment outcomes.
By ensuring a consistent supply of Cu-64, the company aims to expand its targeted copper theranostics program, which focuses on precision-based treatments. This initiative aligns with Clarity’s broader mission of advancing innovative therapies for conditions with high unmet medical needs.
Regulatory Recognition Fast-Tracks Development
A significant milestone for Clarity is the recent fast-track designation (FTD) granted by the U.S. Food and Drug Administration (FDA) for its 64Cu-SAR-bisPSMA product. This designation will expedite the development of treatments for prostate cancer patients undergoing pre-prostatectomy procedures and those experiencing biochemical recurrence.
Regulatory recognition highlights the growing demand for improved prostate cancer imaging solutions, as existing first-generation PSMA products leave room for enhanced diagnostic and treatment options. Clarity’s targeted approach has the potential to redefine how prostate cancer is diagnosed and managed, providing clinicians with better tools for early detection and precision treatment.
Addressing a Global Health Challenge
Prostate cancer remains one of the most prevalent cancers among men and is the fifth leading cause of cancer-related deaths worldwide. Late-stage diagnoses often result in poor treatment outcomes, underscoring the urgent need for advanced diagnostic and therapeutic solutions.
AIBN’s state-of-the-art radiochemistry facilities will play a pivotal role in supporting Clarity’s initiatives by supplying Cu-64 on a weekly basis to research sites across Australia. This agreement not only strengthens domestic supply chains but also reinforces the company’s commitment to advancing next-generation cancer treatments.
